Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39 CHF | +2.23% | -.--% | +2.23% |
04/07 | BRITISH AMERICAN TOBACCO : JP Morgan reiterates its Neutral rating | ZD |
03/07 | BRITISH AMERICAN TOBACCO : RBC reiterates its Neutral rating | ZD |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- One of the major weak points of the company is its financial situation.
- The company's enterprise value to sales, at 3.28 times its current sales, is high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Tobacco
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.23% | 6.98TCr | - | ||
+8.55% | 16TCr | B- | ||
+32.46% | 676.53Cr | B- | ||
+105.47% | 269.86Cr | - | C+ | |
-1.41% | 181.94Cr | - | ||
-6.03% | 166.86Cr | - | D+ | |
-28.70% | 118.33Cr | - | B+ | |
0.00% | 64Cr | - | - | |
+25.61% | 58Cr | C+ | ||
-36.27% | 44Cr | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BATS Stock
- BATS Stock
- Ratings British American Tobacco p.l.c.